Esperion Therapeutics (NASDAQ:ESPR) Releases Quarterly Earnings Results, Misses Estimates By $0.42 EPS

Esperion Therapeutics (NASDAQ:ESPR) posted its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($2.37) earnings per share for the quarter, missing the consensus estimate of ($1.95) by ($0.42), Fidelity Earnings reports. The firm had revenue of $0.98 million during the quarter, compared to the consensus estimate of $0.99 million. During the same period in the prior year, the company earned ($1.86) earnings per share.

NASDAQ ESPR traded up $0.25 during trading hours on Friday, hitting $37.82. 592,400 shares of the company traded hands, compared to its average volume of 500,623. The stock has a market capitalization of $1.11 billion, a price-to-earnings ratio of -5.02 and a beta of 1.86. Esperion Therapeutics has a twelve month low of $33.13 and a twelve month high of $58.90. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.65 and a current ratio of 5.65. The business’s 50-day moving average is $38.49 and its 200-day moving average is $42.58.

Several research analysts have recently weighed in on ESPR shares. Cowen reaffirmed a “buy” rating on shares of Esperion Therapeutics in a research report on Wednesday. ValuEngine raised Esperion Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. BidaskClub raised Esperion Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, October 29th. Northland Securities reaffirmed a “buy” rating on shares of Esperion Therapeutics in a research report on Thursday, August 29th. Finally, Stifel Nicolaus reduced their price objective on Esperion Therapeutics from $112.00 to $70.00 and set a “buy” rating for the company in a research report on Tuesday, September 17th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, five have given a buy rating and two have issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $70.44.

In related news, major shareholder Target N. V. Biotech purchased 80,000 shares of Esperion Therapeutics stock in a transaction that occurred on Wednesday, September 4th. The shares were acquired at an average price of $33.78 per share, with a total value of $2,702,400.00. Following the completion of the transaction, the insider now directly owns 3,652,964 shares of the company’s stock, valued at approximately $123,397,123.92. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Target N. V. Biotech purchased 75,000 shares of Esperion Therapeutics stock in a transaction that occurred on Wednesday, November 6th. The shares were bought at an average cost of $37.30 per share, for a total transaction of $2,797,500.00. Following the transaction, the insider now directly owns 3,727,964 shares of the company’s stock, valued at $139,053,057.20. The disclosure for this purchase can be found here. Insiders have purchased 167,500 shares of company stock worth $5,943,925 in the last three months. 7.70% of the stock is currently owned by company insiders.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

Featured Story: What are different types of coverage ratios?

Earnings History for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.